Tvardi TherapeuticsLTS:0HTC 12 FCF Yield % is -120.93 as of Jun. 30, 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Tvardi Therapeutics ranks worse than 92.23% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Tvardi Therapeutics FCF Yield % Related Terms
Tvardi Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Tvardi Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HTC vs HOWL, TPST, XCUR: FCF Yield % Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tvardi Therapeutics (LTS:0HTC) has a FCF Yield % of -120.93 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #1305 out of 1415 companies in the Biotechnology industry, placing it in the top 92.2%.
Is Tvardi Therapeutics' FCF Yield % too high?
Tvardi Therapeutics' current FCF Yield % is -120.93. Based on the distribution chart, Tvardi Therapeutics ranks #1305 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' FCF Yield % compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #1305 out of 1415 companies for FCF Yield %. This places Tvardi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current FCF Yield % is -120.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current FCF Yield % of -120.93. The current FCF Yield % is -120.93. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current FCF Yield % is -120.93 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTC has been successfully added to your 